Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ACR-368, either alone or combined with ultra-low dose gemcitabine ULDG sensitization, in adults with high-grade endometrial cancer. This Phase 2 open-label study divides participants into four groups based on tumor characteristics and prior test results to better understand treatment responses. Participants are assigned to one of four groups two based on tumor sensitivity predicted by the OncoSignature test, and two without this selection. Those in Arms 1 and 4 receive ACR-368 alone, while Arms 2 and 3 receive ACR-368 combined with ULDG sensitization. Treatment continues until disease progression, unacceptable side effects, or withdrawal. During the study, participants undergo tumor response assessments every 8 weeks for up to 2 years or until death. Safety is monitored through adverse event tracking and limited pharmacokinetic testing. Researchers also observe overall survival, duration of response, and progression-free survival throughout the follow-up period ending at 2 years.
Actively Recruiting
Researchers are studying the effects of combining an experimental drug called fianlimab REGN3767 with cemiplimab, compared to cemiplimab with a placebo, in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC that has not been previously treated. The study focuses on patients whose cancer is positive for PD-L1 expression and aims to understand side effects, drug levels in the blood, and immune responses to the treatments. Participants are divided into two groups based on HPV status one with HPV-positive HNSCC and the other with HPV-negative HNSCC. Each group is randomly assigned to receive either the combination of fianlimab and cemiplimab or cemiplimab with placebo. Both treatments are given as fixed-dose combinations according to the study protocol. During the study, participants will be monitored for up to about 58 months, including assessments of overall response rate, disease control, progression-free survival, and duration of response. Researchers will also track various types of adverse events and measure drug concentrations and antibody responses in the blood. Safety and treatment effects will be evaluated throughout and up to 90 days after the last treatment dose.